I just saw that they entered a partnership with Baxter to develop Pacritinib. With good study results, the drug could reach market in 2 years or a bit less.
Interesting compound said to owe all its activity to JAK-2 inhibition (although it also inhibits FLT-3). Generally good pharmacology although the 400 mg/day dose is high enough to get you to look for off-target effects (and diarrhea is reported). Very distinct structure from most disclosed Intermune compounds suggests that some patients resistant to Jakafi may be helped.
I don't think this is a threat to Jakafi's first-line status. The drug has very little anti-JAK1 activity, and Incyte results suggest that JAK1 is important in MF morbidity (feeling sick). There is no particular reason to expect one JAK2 inhibitor to be less myelosuppressive than another, so the low myelosuppression seen in early trials suggests that the drug is being under-dosed to avoid problems. In fact, a worrisome pneumonia signal is seen in early studies.